Please login to the form below

Not currently logged in
Email:
Password:

Cinven

This page shows the latest Cinven news and features for those working in and with pharma, biotech and healthcare.

UK’s CMA fines drugmakers £260m for overcharging NHS for steroid med

UK’s CMA fines drugmakers £260m for overcharging NHS for steroid med

Advanz and its former parent Cinven has also been fined a total of £43m for their part in the collision, while Waymade has also been fined £2.5m.

Latest news

  • Stada's €4.1bn takeover goes through Stada's €4.1bn takeover goes through

    The buyout - which is the largest for a European-listed company for years - came after Stada and Cinven secured the acceptance of 63.85% of Stada's shareholders, just above the

  • Time running out on new Stada takeover bid Time running out on new Stada takeover bid

    Bain and Cinven narrowly failed to reach the required acceptance threshold for an earlier offer, mustering support from 65.52% of investors, just shy of the 67.5% needed to seal ... The proposed deal - which would be Europe's largest private equity

  • Trouble at the top of Stada as Bain and Cinven mull fresh bid Trouble at the top of Stada as Bain and Cinven mull fresh bid

    The chief executive and finance chief of Stada have stepped down in the wake of the failed takeover by private equity firms Bain and Cinven, citing "personal reasons". ... The news comes as Bain and Cinven are reportedly preparing a fresh bid that would

  • No deal for Stada as private equity takeover bid collapses No deal for Stada as private equity takeover bid collapses

    Bain Capital and Cinven's planned buyout of Germany's Stada has failed at the last hurdle, with too few of Stada's shareholders agreeing to the deal by the deadline. ... Stada's board had lent its support to the Bain-Cinven offer over a rival 58 per

  • Private equity firms agree deal to take over Stada Private equity firms agree deal to take over Stada

    Cinven and Bain Capital made what Stada said was the "most financially appealing offer" of 66 per share, topping an earlier bid from Advent International of 58. ... Cinven partners Supraj Rajagopalan and Bruno Schick said the aim is to help the company

More from news
Approximately 7 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch - May 2017 Deal Watch - May 2017

    Given this background what do we make of the deal where two private equity companies, Bain and Cinven, joined forces to acquire Stada for $5.63bn? ... in 2015 for $3.5bn.  The price was said to be 5 x Cinven’s original investment.  Not a bad return

  • Deal Watch February 2017 Deal Watch February 2017

    Earlier in the month the private equity (PE) firm Cinven offered 56 a share to acquire Stada but this has been topped by a binding offer from another PE company, Advent

  • Pharma deals in September 2015 Pharma deals in September 2015

    Transformational deals. The two largest deals announced this month were Cinven's sale of Amdipharm Mercury (AMCo) to Concordia Healthcare and Actelion's move to acquire ZS Pharma, at $3.5bn

  • Deal Watch table for February 2014 Deal Watch table for February 2014

    1, 225. Medpace / Cinven. Acquisition – majority shareholding. US mid-sized CRO with global presence.

  • Pharma deals during October 2012 Pharma deals during October 2012

    680. Amdipharm / Cinven. Acquisition. Portfolio of off-patent “legacy products”. 590.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....